The epidermal growth factor receptor (EGRF) in lung cancer

Translational Respiratory Medicine

Table 1 Phase III trials of EGFR TKIs versus chemotherapy as first line therapy in NSCLC EGFR mutated patients

Study	TKI	Chemotherapy	Population	Response rate (EGFR TKI vs chemotherapy) %		Disease control rate (EGFR TKI vs chemo) %		Progression free survival (EGFR TKI vs chemo) m		Overall survival (EGFR TKI vs chemo) m
IPASS (Sub-study) ¹	Gefitinib	Carbo/Pac	Asian (E/SE)	71.2	47.3	91.7	87.6	9	6	21.6	21.9
				p 0.001				p 0.001		NS
EURTAC ²	Erlotinib	Cis OR Carbo + Doc OR Gem	Caucasian	58	15	79	66	9.4	5.2	NR	NR
				p < 0.001		p <0.001		p < 0.0001
OPTIMAL ³	Erlotinib	Carbo/Gem	Asian (China)	83	36	96	82	13.1	4.6	NR	NR
				p 0.00001		p <0.0001		p < 0.0001
WJTOG 3405 ⁴	Gefitinib	Cis/Doc	Asian (Japan)	62.1	32.2	93.1	78	9.2	6.3	30.9	NR
				p < 0.0001		p 0.02		p < 0.0001		p 0.211
NEJSG 002 ⁵	Gefitinib	Carbo/Pac	Asian (Japan)	73.7	30	86	79	10.8	5.4	30.5	23.6
				p < 0.001				p < 0.001		p 0.353
LUX-Lung 3 ⁶	Afatinib	Cis/Pem	Majority Asian	56.1	22.6	NR	NR	11.1	6.9	31.6	28.2
				p < 0.0001				p 0.0004		p 0.109
LUX-Lung 6 ⁷	Afatinib	Cis/Gem	Asian (E/SE)	67	23	93	76	11	5.6	23.6	23.5
				p < 0.0001		p < 0.0001		p 0.001		p0.175

¹Mok, et al. N Engl J Med 2009 [36]; ²; ²Rosell, et al. Lancet Oncol 2012 [40]; ³Zhou, et al. Lancet Oncol 2011 [39]; ⁴Mitsudomi, et al. Lancet Oncol 2010 [37]; ⁵Maemondo, et al. N Engl J Med 2010 [38]; ⁶Sequist, et al. J Clin Oncol 2013 [43]; ⁷Wu, et al. ASCO 2013 [44].